Cargando…

DNA Vaccine Treatment in Dogs Experimentally Infected with Trypanosoma cruzi

Chagas disease is a chronic and potentially lethal disorder caused by the parasite Trypanosoma cruzi, and an effective treatment has not been developed for chronic Chagas disease. The objective of this study was to determine the effectiveness of a therapeutic DNA vaccine containing T. cruzi genes in...

Descripción completa

Detalles Bibliográficos
Autores principales: Arce-Fonseca, Minerva, Carbajal-Hernández, Ana C., Lozano-Camacho, Mónica, Carrillo-Sánchez, Silvia del C., Roldán, Francisco-Javier, Aranda-Fraustro, Alberto, Rosales-Encina, José Luis, Rodríguez-Morales, Olivia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7222601/
https://www.ncbi.nlm.nih.gov/pubmed/32455143
http://dx.doi.org/10.1155/2020/9794575
_version_ 1783533611523244032
author Arce-Fonseca, Minerva
Carbajal-Hernández, Ana C.
Lozano-Camacho, Mónica
Carrillo-Sánchez, Silvia del C.
Roldán, Francisco-Javier
Aranda-Fraustro, Alberto
Rosales-Encina, José Luis
Rodríguez-Morales, Olivia
author_facet Arce-Fonseca, Minerva
Carbajal-Hernández, Ana C.
Lozano-Camacho, Mónica
Carrillo-Sánchez, Silvia del C.
Roldán, Francisco-Javier
Aranda-Fraustro, Alberto
Rosales-Encina, José Luis
Rodríguez-Morales, Olivia
author_sort Arce-Fonseca, Minerva
collection PubMed
description Chagas disease is a chronic and potentially lethal disorder caused by the parasite Trypanosoma cruzi, and an effective treatment has not been developed for chronic Chagas disease. The objective of this study was to determine the effectiveness of a therapeutic DNA vaccine containing T. cruzi genes in dogs with experimentally induced Chagas disease through clinical, pathological, and immunological analyses. Infection of Beagle dogs with the H8 T. cruzi strain was performed intraperitoneally with 3500 metacyclic trypomastigotes/kg body weight. Two weeks after infection, plasmid DNA immunotherapy was administered thrice at 15-day intervals. The clinical (physical and cabinet studies), immunological (antibody and cytokine profiles and lymphoproliferation), and macro- and microscopic pathological findings were described. A significant increase in IgG and cell proliferation was recorded after immunotherapy, and the highest stimulation index (3.02) was observed in dogs treated with the pBCSSP4 plasmid. The second treatment with both plasmids induced an increase in IL-1, and the third treatment with the pBCSSP4 plasmid induced an increase in IL-6. The pBCSP plasmid had a good Th1 response regulated by high levels of IFN-gamma and TNF-alpha, whereas the combination of the two plasmids did not have a synergistic effect. Electrocardiographic studies registered lower abnormalities and the lowest number of individuals with abnormalities in each group treated with the therapeutic vaccine. Echocardiograms showed that the pBCSSP4 plasmid immunotherapy preserved cardiac structure and function to a greater extent and prevented cardiomegaly. The two plasmids alone controlled the infection moderately by a reduction in the inflammatory infiltrates in heart tissue. The immunotherapy was able to reduce the magnitude of cardiac lesions and modulate the cellular immune response; the pBCSP treatment showed a clear Th1 response; and pBCSSP4 induced a balanced Th1/Th2 immune response that prevented severe cardiac involvement. The pBCSSP4 plasmid had a better effect on most of the parameters evaluated in this study; therefore, this plasmid can be considered an optional treatment against Chagas disease in naturally infected dogs.
format Online
Article
Text
id pubmed-7222601
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-72226012020-05-23 DNA Vaccine Treatment in Dogs Experimentally Infected with Trypanosoma cruzi Arce-Fonseca, Minerva Carbajal-Hernández, Ana C. Lozano-Camacho, Mónica Carrillo-Sánchez, Silvia del C. Roldán, Francisco-Javier Aranda-Fraustro, Alberto Rosales-Encina, José Luis Rodríguez-Morales, Olivia J Immunol Res Research Article Chagas disease is a chronic and potentially lethal disorder caused by the parasite Trypanosoma cruzi, and an effective treatment has not been developed for chronic Chagas disease. The objective of this study was to determine the effectiveness of a therapeutic DNA vaccine containing T. cruzi genes in dogs with experimentally induced Chagas disease through clinical, pathological, and immunological analyses. Infection of Beagle dogs with the H8 T. cruzi strain was performed intraperitoneally with 3500 metacyclic trypomastigotes/kg body weight. Two weeks after infection, plasmid DNA immunotherapy was administered thrice at 15-day intervals. The clinical (physical and cabinet studies), immunological (antibody and cytokine profiles and lymphoproliferation), and macro- and microscopic pathological findings were described. A significant increase in IgG and cell proliferation was recorded after immunotherapy, and the highest stimulation index (3.02) was observed in dogs treated with the pBCSSP4 plasmid. The second treatment with both plasmids induced an increase in IL-1, and the third treatment with the pBCSSP4 plasmid induced an increase in IL-6. The pBCSP plasmid had a good Th1 response regulated by high levels of IFN-gamma and TNF-alpha, whereas the combination of the two plasmids did not have a synergistic effect. Electrocardiographic studies registered lower abnormalities and the lowest number of individuals with abnormalities in each group treated with the therapeutic vaccine. Echocardiograms showed that the pBCSSP4 plasmid immunotherapy preserved cardiac structure and function to a greater extent and prevented cardiomegaly. The two plasmids alone controlled the infection moderately by a reduction in the inflammatory infiltrates in heart tissue. The immunotherapy was able to reduce the magnitude of cardiac lesions and modulate the cellular immune response; the pBCSP treatment showed a clear Th1 response; and pBCSSP4 induced a balanced Th1/Th2 immune response that prevented severe cardiac involvement. The pBCSSP4 plasmid had a better effect on most of the parameters evaluated in this study; therefore, this plasmid can be considered an optional treatment against Chagas disease in naturally infected dogs. Hindawi 2020-05-05 /pmc/articles/PMC7222601/ /pubmed/32455143 http://dx.doi.org/10.1155/2020/9794575 Text en Copyright © 2020 Minerva Arce-Fonseca et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Arce-Fonseca, Minerva
Carbajal-Hernández, Ana C.
Lozano-Camacho, Mónica
Carrillo-Sánchez, Silvia del C.
Roldán, Francisco-Javier
Aranda-Fraustro, Alberto
Rosales-Encina, José Luis
Rodríguez-Morales, Olivia
DNA Vaccine Treatment in Dogs Experimentally Infected with Trypanosoma cruzi
title DNA Vaccine Treatment in Dogs Experimentally Infected with Trypanosoma cruzi
title_full DNA Vaccine Treatment in Dogs Experimentally Infected with Trypanosoma cruzi
title_fullStr DNA Vaccine Treatment in Dogs Experimentally Infected with Trypanosoma cruzi
title_full_unstemmed DNA Vaccine Treatment in Dogs Experimentally Infected with Trypanosoma cruzi
title_short DNA Vaccine Treatment in Dogs Experimentally Infected with Trypanosoma cruzi
title_sort dna vaccine treatment in dogs experimentally infected with trypanosoma cruzi
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7222601/
https://www.ncbi.nlm.nih.gov/pubmed/32455143
http://dx.doi.org/10.1155/2020/9794575
work_keys_str_mv AT arcefonsecaminerva dnavaccinetreatmentindogsexperimentallyinfectedwithtrypanosomacruzi
AT carbajalhernandezanac dnavaccinetreatmentindogsexperimentallyinfectedwithtrypanosomacruzi
AT lozanocamachomonica dnavaccinetreatmentindogsexperimentallyinfectedwithtrypanosomacruzi
AT carrillosanchezsilviadelc dnavaccinetreatmentindogsexperimentallyinfectedwithtrypanosomacruzi
AT roldanfranciscojavier dnavaccinetreatmentindogsexperimentallyinfectedwithtrypanosomacruzi
AT arandafraustroalberto dnavaccinetreatmentindogsexperimentallyinfectedwithtrypanosomacruzi
AT rosalesencinajoseluis dnavaccinetreatmentindogsexperimentallyinfectedwithtrypanosomacruzi
AT rodriguezmoralesolivia dnavaccinetreatmentindogsexperimentallyinfectedwithtrypanosomacruzi